Cathepsins and age-related macular degeneration: A Mendelian randomization study unveiling causal relationships
- PMID: 40355192
- PMCID: PMC12073853
- DOI: 10.1097/MD.0000000000042357
Cathepsins and age-related macular degeneration: A Mendelian randomization study unveiling causal relationships
Abstract
Age-related macular degeneration (AMD) is a leading cause of vision impairment and blindness in older adults, profoundly affecting millions of individuals worldwide. Cathepsins are a crucial class of proteolytic enzymes that participates in multiple biological process. However, the role of cathepsins in AMD still remains unclear. This study aims to probe into the causal relationship between cathepsins and AMD using a 2-sample Mendelian randomization (MR). Instrumental variables associated with exposure (cathepsins) and the outcome (AMD) were sourced from published genome-wide association studies. To estimate the causal effects, methodologies such as inverse variance weighted, MR-Egger, and weighted median estimation (WM) were employed. Reverse MR and multivariate MR analyses were also performed. The elevated levels of cathepsin B significantly increased the risk of dry AMD, with an odds ratio (OR) of 1.068 (95% CI = 1.007-1.133) and a P-value of .029). Sensitivity analyses confirmed the robustness of these findings, with no evidence of heterogeneity or pleiotropy. Reverse MR analyses indicated that total AMD might elevate levels of cathepsin E (OR = 1.04, P = .029). Multivariate MR analysis showed significant associations between specific cathepsins and AMD subtypes, including cathepsin G and cathepsin O with significantly increasing risk. The study revealed a potential causal effect of cathepsin B on AMD, especially dry AMD. These findings provide potential therapeutic targets for AMD, and further research is needed to understand the underlying mechanisms.
Keywords: Mendelian randomization; age-related macular degeneration; cathepsin.
Copyright © 2025 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures



Similar articles
-
Cysteine cathepsins and autoimmune diseases: A bidirectional Mendelian randomization.Medicine (Baltimore). 2024 Oct 25;103(43):e40268. doi: 10.1097/MD.0000000000040268. Medicine (Baltimore). 2024. PMID: 39470488 Free PMC article.
-
Association between cathepsins and cardiomyopathy: A Mendelian randomization study.Medicine (Baltimore). 2024 Dec 20;103(51):e40974. doi: 10.1097/MD.0000000000040974. Medicine (Baltimore). 2024. PMID: 39705476 Free PMC article.
-
Genetic insights into the role of cathepsins in cardiovascular diseases: a Mendelian randomization study.ESC Heart Fail. 2024 Oct;11(5):2707-2718. doi: 10.1002/ehf2.14826. Epub 2024 May 7. ESC Heart Fail. 2024. PMID: 38714485 Free PMC article.
-
Causal association between metabolites and age-related macular degeneration: a bidirectional two-sample mendelian randomization study.Hereditas. 2024 Dec 20;161(1):51. doi: 10.1186/s41065-024-00356-6. Hereditas. 2024. PMID: 39707561 Free PMC article.
-
Genetic Insights Into the Role of Cathepsins in Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis: Evidence From Mendelian Randomization Study.Brain Behav. 2025 Jan;15(1):e70207. doi: 10.1002/brb3.70207. Brain Behav. 2025. PMID: 39740768 Free PMC article.
References
-
- Guymer RH, Campbell TG. Age-related macular degeneration. Lancet. 2023;401:1459–72. - PubMed
-
- Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024;331:147–57. - PubMed
-
- Thomas CJ, Mirza RG, Gill MK. Age-related macular degeneration. Med Clin North Am. 2021;105:473–91. - PubMed
-
- van Lookeren Campagne M, LeCouter J, Yaspan BL, Ye W. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol. 2014;232:151–64. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical